Drug · CHEMBL2364655
EVOLOCUMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EVOLOCUMAB. Drugs and targets, record CHEMBL2364655. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL2364655
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | Subtilisin/kexin type 9 inhibitor | INHIBITOR | https://conductscience.org/library/genes/255738 |
Source ChEMBL
Diseases27
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Hypercholesterolemia | Approval | EMA Human Drugs and PMDA | 19 | 17 | https://conductscience.org/library/drugs?q=HP_0003124 |
| acute coronary syndrome | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005542 |
| familial hypercholesterolemia | Approval | DailyMed and PMDA | 12 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005439 |
| coronary artery disorder | Approval | DailyMed | 10 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005010 |
| cardiovascular disorder | Approval | ATC and DailyMed | 10 | 8 | https://conductscience.org/library/drugs?q=MONDO_0004995 |
| hyperlipidemia | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0021187 |
| Combined hyperlipidemia | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=Orphanet_79211 |
| myocardial infarction | Approval | DailyMed | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
| acute myocardial infarction | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0004781 |
| type 2 diabetes mellitus | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
1 to 10 of 27Source Open Targets
See all 27 diseasesTrials138
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01764633 | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk | Phase 3 | 27,564 | 2018-02-15 | evolocumab | Its name | ClinicalTrials.gov |
| NCT02867813 | Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension | Phase 3 | 5,035 | 2023-02-28 | evolocumab | Its name | ClinicalTrials.gov |
| NCT01854918 | Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia | Phase 3 | 3,681 | 2019-06-11 | evolocumab | Its name | ClinicalTrials.gov |
| NCT01763866 | LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 | Phase 3 | 2,067 | 2015-12-22 | evolocumab | Its name | ClinicalTrials.gov |
| NCT02207634 | Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects | Phase 3 | 1,974 | 2018-01-16 | evolocumab | Its name | ClinicalTrials.gov |
| NCT03080935 | Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries | Phase 3 | 1,600 | 2023-01-11 | evolocumab | Its name | ClinicalTrials.gov |
| NCT01439880 | Open Label Study of Long Term Evaluation Against LDL-C Trial | Phase 2 | 1,324 | 2019-07-10 | evolocumab | Its name | ClinicalTrials.gov |
| NCT02662569 | Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia | Phase 3 | 986 | 2019-01-11 | evolocumab | Its name | ClinicalTrials.gov |
| NCT01813422 | GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound | Phase 3 | 970 | 2018-01-04 | evolocumab | Its name | ClinicalTrials.gov |
| NCT01516879 | Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study | Phase 3 | 905 | 2015-09-29 | evolocumab | Its name | ClinicalTrials.gov |
1 to 10 of 138
See all 138 trialsComparisons in its trials35
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Evolocumab vs Placebo: serious adverse events | 3,410 of 13,769 | 3,404 of 13,756 | 27,525 | NCT01764633 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 287 of 2,500 | 309 of 2,535 | 5,035 | NCT02867813 | Trial comparisons |
Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 2,084 of 2,499 | 2,144 of 2,532 | 5,031 | NCT02867813 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 1,045 of 2,499 | 1,077 of 2,532 | 5,031 | NCT02867813 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 212 of 983 | 204 of 990 | 1,973 | NCT02207634 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 51 of 855 | 35 of 745 | 1,600 | NCT03080935 | Trial comparisons |
Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 810 of 854 | 686 of 745 | 1,599 | NCT03080935 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 410 of 854 | 323 of 745 | 1,599 | NCT03080935 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 135 of 484 | 142 of 484 | 968 | NCT01813422 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 33 of 599 | 13 of 302 | 901 | NCT01516879 | Trial comparisons |
1 to 10 of 35
See all 35 comparisons in its trialsPapers from its trials130
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Choice Reaction Time | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL2364655
GET https://conductscience.org/api/drugs/v1/CHEMBL2364655/diseases?page=2